A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.

Clinical Trial ID NCT00391092

PubWeight™ 17.67^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00391092

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Treatment of HER2-positive breast cancer: current status and future perspectives.	Nat Rev Clin Oncol	2011	4.12
2	AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.	J Clin Oncol	2013	1.77
3	Targeting tumor cell motility to prevent metastasis.	Adv Drug Deliv Rev	2011	1.32
4	Current approaches and future directions in the treatment of HER2-positive breast cancer.	Cancer Treat Rev	2012	1.23
5	Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.	Breast Cancer Res	2009	1.20
6	Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer.	Br J Cancer	2012	1.12
7	Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence.	J Oncol	2012	1.03
8	Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.	Curr Opin Obstet Gynecol	2011	1.03
9	Molecular targeted therapies for breast cancer treatment.	Breast Cancer Res	2008	1.03
10	Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.	Biochim Biophys Acta	2014	0.96
11	Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer.	Int J Breast Cancer	2012	0.92
12	Bevacizumab and breast cancer: current therapeutic progress and future perspectives.	Expert Rev Anticancer Ther	2009	0.80
13	Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies.	Ther Adv Med Oncol	2016	0.75
14	Novel combinations for the treatment of metastatic breast cancer.	Cancers (Basel)	2010	0.75